BRUKER CORP (BRKRP) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-06

Key Insights

Bruker Corporation announced Q1 2026 financial results on May 6, 2026, with the press release containing forward-looking statements that indicate management's confidence in future performance.
The company has both common stock (BRKR) and mandatory convertible preferred stock (BRKRP) trading on Nasdaq, indicating a capital structure with preferred equity holders having specific conversion rights and dividend obligations at 6.375%.
The 8-K filing is limited to earnings announcement and does not disclose material agreements, executive changes, or significant corporate events, suggesting this is a routine quarterly earnings report with no major developments.

Want the newest filings?

This analysis covers the filing from 2026-05-06. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-28

Bruker declared a quarterly dividend of $3.9844 per share on its 6.375% Mandatory Convertible Preferred Stock, Series A, payable June 1, 2026, indicating the company continues to service its preferred equity obligations on schedule.
This is a routine dividend declaration on preferred stock, suggesting stable operations and continued capital allocation to preferred shareholders without material business impact.
The filing contains no material business developments, strategic announcements, or material events beyond the routine preferred dividend declaration, representing standard ongoing corporate governance.

Filed: 2026-04-10

Bruker Corporation announced the departure of Falko Busse, Ph.D., an executive officer and President of the Bruker BioSpin Group, effective October 31, 2026. The company has agreed to provide separation benefits including severance, bonus, and vacation payout totaling approximately $1,020,351.
The departure of a key executive could signal changes in the company's leadership or business strategy, which may impact investor sentiment and the stock price.
The company will need to find a suitable replacement for the Bruker BioSpin Group president role, which could affect the division's operations and performance.

Filed: 2026-04-01

Bruker Corporation has appointed Thierry L. Bernard, the current CEO and Managing Director of QIAGEN N.V., to its Board of Directors, effective April 1, 2026.
Mr. Bernard has over 15 years of experience in the biotech and diagnostics industry, including senior leadership roles at bioMérieux SA and QIAGEN.
The addition of Mr. Bernard to the Board suggests Bruker may be looking to leverage his industry expertise and connections to drive growth and strategic initiatives.

Filed: 2026-02-20

Bruker Corporation announced the retirement of a director, Dr. Cynthia M. Friend, who will not stand for re-election at the 2026 Annual Meeting.
The company's board of directors elected Jack Phillips, a current director, to a new Class II position and he will stand for re-election at the 2026 Annual Meeting.
Bruker Corporation declared a quarterly cash dividend of $0.05 per share on its common stock, payable on April 7, 2026 to shareholders of record on March 23, 2026.

Other reports for BRUKER CORP

Quarterly Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.